Melanoma
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
Forward Look
Tackling Drug ResistanceResearchers are studing new ways to keep treatments working longer.
by Stephen Ornes
-
Survivor Profile
Living in the Here and NowA metastatic melanoma survivor is hopeful but realistic as new treatments become available.
by Jenny Song
-
Forward Look
Cancer Immunotherapies Continue to Make HeadwayDrugs that harness the power of the immune system gain new approvals.
by Alexandra Goho
-
Survivor Profile
Knowing Her OptionsWhen Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors.
by Melissa Davlin
-
First Person
Keeping Sight of HopeA survivor keeps an eye on what's ahead after a rare cancer diagnosis.
by Sue Russell
-
Forward Look
Boosting Defenses Against CancerQ&A with immunologist James P. Allison, Memorial Sloan-Kettering Cancer Center, New York City.
by Ingfei Chen
